Beijing Dongfang Baitai Biotechnology Co., Ltd.

Beijing Dongfang Baitai Biotechnology Co., Ltd is a high-tech enterprise dedicated to the research, development, and production of innovative biological drugs, including monoclonal antibodies, fusion proteins, and bispecific antibodies targeting major diseases such as cancer, diabetes, and autoimmune disorders. The company has established an advanced biopharmaceutical technology platform spanning the entire industrial chain, from discovery to commercialization, enabling efficient development of high-potency therapeutics with enhanced efficacy and safety profiles. Its pipeline features over 20 R&D projects, supported by a multidisciplinary team where more than 50% hold master's or doctoral degrees, fostering breakthroughs in antibody engineering and protein fusion technologies. Serving the global biopharma sector, Dongfang Baitai prioritizes precision medicine solutions that address unmet clinical needs, with a focus on scalable manufacturing under GMP standards. Notable achievements include securing over 100 invention patents, recognition as a key innovator in Zhongguancun's biotech ecosystem, and successful progression of multiple candidates toward clinical trials, including a first-phase mammalian cell culture production line set for 2023 commissioning to meet China and U.S. GMP requirements. The company upholds ISO certifications for quality, environmental, and occupational health management, driving sustainable advancements in biotechnology.